Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Inhibikase Therapeutics

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Announces Expansion of Senior Leadership Team
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.